RESTEM is developing, Restem-L, an off-the-shelf and allogeneic cell-based therapeutics to provide patients with rapid and broad to more potent, durable and safe cell-based therapeutics. Restem-L has the potential to treat several autoimmune diseases and as well disease indications with high unmet need. In addition, our aNK cell program targeting cellular senescence has the potential to treat age-related diseases including frailty.
Restem-L, our investigational ULSC therapy has shown incredible promise in potency, safety, and efficacy across numerous autoimmune diseases. In preclinical and clinical studies, it was shown that these ULSCs have a superior immunomodulatory profile compared to other types of mesenchymal stem cells (MSCs) such as bone marrow or fat MSCs.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.